Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents
Clinical trial NCT06477653 · RECRUITING
Trial details
- NCT number
- NCT06477653
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-05
- Primary completion
- 2026-12-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.